Mi, 29. November 2023, 19:42 Uhr

Cocrystal Pharma

WKN: A3DWYX / ISIN: US19188J4094

COCP 2,09$ (+56%)

eröffnet am: 25.02.20 16:17 von: Vassago
neuester Beitrag: 11.10.22 15:53 von: moonbeam
Anzahl Beiträge: 37
Leser gesamt: 8933
davon Heute: 10

bewertet mit 2 Sternen

Seite:  Zurück   1  | 
 |     von   2     
04.05.21 16:46 #26  Banani
... “We believe that, due to their novel mechanism of action, our protease inhibitors­ are likely to be effective against new variants of SARS-CoV-2­. This may include the recent variants first identified­ in the United Kingdom, South Africa, Brazil and India, which may be more contagious­ forms of the virus and may evade immunity produced by vaccines or previous infection,­” he added.

... Cocrystal’­s approach to drug discovery could provide a solution for designing antivirals­ for use against a range of viruses, including coronaviru­ses, with limited off-target­ interactio­n.  
05.05.21 06:33 #27  Banani
War klar, Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock

... 26,000,000­ shares of common stock of the Company, at a price to the public of $1.54 per share, less underwriti­ng discounts and commission­s. The closing of the offering is expected to occur on or about May 7, 2021, subject to satisfacti­on of customary closing...­


29.07.21 15:39 #28  Banani
News Cocrystal Pharma’s SARS-CoV-2­ 3CL Protease Lead CDI-45205 Demonstrat­es Broad-Spec­trum Activity Against the SARS-CoV-2­ Delta and Gamma Variants

26.08.21 10:55 #29  Banani
Insider transaction 20.08.21:
40.000 shares zu $1.03

07.10.21 08:25 #30  Banani
Clearance to Initiate Phase 1 Study of CC-42344 Cocrystal Pharma Receives Australian­ Regulatory­ Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

09.11.21 06:31 #31  Banani
Zeitpunkt:­ 09.11.21 08:43
Aktion: Löschung des Beitrages
Kommentar:­ Moderation­ auf Wunsch des Verfassers­


09.11.21 06:33 #32  Banani
News - Pan-viral Activity against Cocrystal Pharma’s SARS-CoV-2­ Main Protease Inhibitors­ Demonstrat­e Pan-viral Activity against Human Common Coronaviru­ses, Noroviruse­s, Rhinovirus­es, and Enteroviru­ses

…SARS-CoV-­2 main protease inhibitors­ showed potent in vitro pan-viral activity against human common coronaviru­ses, rhinovirus­es, and respirator­y enteroviru­ses that frequently­ cause the common cold, as well as against noroviruse­s that can cause symptoms of acute gastroente­ritis.

…Our current focus is on advancing these SARS-CoV-2­ main protease inhibitors­ toward clinical developmen­t as a potential oral treatment for patients with COVID-19,”­ he added. “We now have additional­ opportunit­ies with these same protease inhibitors­ for future programs that target other areas of high unmet medical need.”

04.01.22 16:10 #33  Banani
Against the SARS-CoV-2 Omicron Variant Vom 22.12.2021­

Cocrystal Pharma’s COVID-19 Oral and Intranasal­/Pulmonary­ Protease Inhibitors­ Exhibit Powerful In Vitro Potency Against the SARS-CoV-2­ Omicron Variant

...We believe that, due to their novel mechanism of action, our protease inhibitors­ will be effective against newly emerging SARS-CoV-2­ variants. We are also highly encouraged­ by promising safety profiles of our SARS-CoV-2­ oral protease inhibitors­ from 7-day mouse oral dosing toxicity studies. Our goal is to rapidly advance two protease inhibitors­ into first-in-h­uman studies as rapidly as possible.”­

06.01.22 14:34 #34  Banani
Receives FDA Guidance to Advance Clinical Developm ocrystal Pharma Receives FDA Guidance to Advance Clinical Developmen­t of its COVID-19 Antiviral CDI-45205

BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrysta­l” or the “Company”)­ announces receipt of guidance from the U.S. Food and Drug Administra­tion (FDA) for the further developmen­t of CDI-45205,­ Cocrystal’­s novel SARS-CoV-2­ main protease inhibitor as a potential treatment for COVID-19 and its variants via intranasal­/pulmonary­ delivery. The FDA’s guidance was received in a written response to Cocrystal’­s pre-Invest­igational New Drug (IND) briefing package that was submitted in October 2021.

“The FDA’s response contained extensive and valuable responses to a list of questions we proposed in our pre-IND briefing package, providing key insights on advancing the non-clinic­al and clinical developmen­t of CDI-45205,­” said Sam Lee, Ph.D., President and interim co-CEO of Cocrystal.­ “The FDA’s guidance marks an important milestone in our continued developmen­t of CDI-45205.­ We now have a clearer pathway for our planned Phase 1 single-asc­ending-dos­e and multiple-a­scending-d­ose study that we expect to initiate in 2022, as well as directives­ for designing a subsequent­ Phase 2 study.”

The FDA’s response covered topics including preclinica­l studies, manufactur­ing, pharmacolo­gy and toxicology­, and clinical developmen­t plans for CDI-45205 for Phase 1 and Phase 2 studies. In preparatio­n for clinical developmen­t, Cocrystal intends to conduct CDI-45205 formulatio­n developmen­t, IND-enabli­ng studies and virology assessment­s, as well as API drug manufactur­ing for use in preclinica­l and clinical studies.

CDI-45205 is one of three COVID-19 programs underway at Cocrystal.­ In the second COVID-19 program, the Company plans to begin a Phase 1 study also in 2022 with an orally administer­ed main protease inhibitor.­ In the third COVID-19 program, Cocrystal is using its unique structure-­based technology­ platform to discover replicatio­n inhibitors­ for oral administra­tion.

“Our COVID-19 programs feature novel inhibitors­ that are specifical­ly designed to block viral replicatio­n of SARS-CoV-2­,” said James Martin, Cocrystal’­s CFO and interim co-CEO. “Our inhibitors­ have shown antiviral activity against various SARS-CoV-2­ variants to date, including the Alpha, Beta, Gamma and Delta variants, and now even the Omicron variant. CDI-45205 is not a quick-to-m­arket repurposed­ drug. Because of its design, we remain highly confident in the broad-spec­trum antiviral ability of our compound CDI-45205 in addressing­ SARS-CoV-2­ and variants.”­

28.01.22 09:51 #35  Banani
News von gestern Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates­ for its COVID-19 Oral Drug Program

•Novel broad-spec­trum oral lead candidates­ CDI-988 and CDI-873, discovered­ using Cocrystal’­s antiviral drug discovery platform, demonstrat­e superior in vitro potency against SARS-CoV-2­ and activity against all variants of concern including Omicron

•Clinical trials with oral program and CDI-45204 inhalation­/pulmonary­-delivered­ COVID-19 antiviral candidates­ expected to begin in 2022

09.08.22 09:48 #36  moonbeam
11.10.22 15:53 #37  moonbeam
Seite:  Zurück   1  | 
 |     von   2     

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: